Literature DB >> 2955387

[Spontaneous dissection of the exocranial internal carotid artery. Therapeutic aspects].

E Landre, F X Roux, C Cioloca.   

Abstract

Spontaneous dissection of the extracranial internal carotid artery is uncommon and has been first described in 1959. Since then, 250 cases have been published. The authors report on 5 recent cases and on that occasion, they review the literature and discuss the different therapeutic possibilities. This pathology can be envisaged when a middle-aged adult, free of any previous pathology or trauma, presents with latero-cervical pain followed by cerebral ischemic stroke. The angiographic findings are of three types: regular or irregular extensive stenosis, pseudo-aneurysmal dilatation followed by luminal stenosis, funnel-like tapering of the vessel. The spontaneous course of such a dissection most often (80%) leads to an almost complete resolution of clinical and angiographic signs. Treatment, therefore, should essentially be based on anticoagulant and antiaggregant therapy, so as to prevent ischemic attacks or carotid thrombosis. Surgical indications should remain exceptional.

Entities:  

Mesh:

Year:  1987        PMID: 2955387

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  2 in total

Review 1.  Antiplatelets or anticoagulants? Secondary prevention in cervical artery dissection: an updated meta-analysis.

Authors:  Ei Zune The; Ne Naing Lin; Ching Jocelyn Chan; Jason Cher Wei Loon; Benjamin Yong-Qiang Tan; Chee Seong Raymond Seet; Hock Luen Teoh; Joy Vijayan; Leong Litt Leonard Yeo
Journal:  Neurol Res Pract       Date:  2022-06-13

Review 2.  Antiplatelets versus anticoagulants for the treatment of cervical artery dissection: Bayesian meta-analysis.

Authors:  Hakan Sarikaya; Bruno R da Costa; Ralf W Baumgartner; Kathleen Duclos; Emmanuel Touzé; Jean M de Bray; Antti Metso; Tiina Metso; Marcel Arnold; Antonio Arauz; Marcel Zwahlen; Peter Jüni
Journal:  PLoS One       Date:  2013-09-05       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.